Wave Life Sciences director Henry sells $85k in shares

Published 14/08/2025, 01:20
Wave Life Sciences director Henry sells $85k in shares

Christian O. Henry, a director at Wave Life Sciences LTD (NASDAQ:WVE), sold 9,670 ordinary shares of the company on August 13, 2025, for approximately $85,192. The stock, currently trading at $8.76, has shown remarkable strength with a 57% return over the past year. According to InvestingPro data, analyst price targets for Wave Life Sciences range from $9 to $36, suggesting potential upside.

The sales were executed at prices ranging from $8.45 to $9.03 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2024.

On August 11, 2025, Henry also acquired 12,700 shares of Wave Life Sciences as a restricted share unit award with a value of $0. Additionally, he was granted options to purchase 76,200 ordinary shares at an exercise price of $8.105.

Following the sale, Henry directly owns 29,645 shares of Wave Life Sciences.

In other recent news, Wave Life Sciences has garnered attention from multiple research firms, each initiating or reiterating positive ratings on the company. Canaccord Genuity initiated coverage with a Buy rating, citing the company’s strong pipeline of RNA-based medicines, including WVE-006, which is expected to release multidose data in the third quarter of 2024. Oppenheimer also initiated coverage with an Outperform rating, highlighting the company’s innovative PRISM platform that supports four clinical-stage programs. Citi joined the positive sentiment with a Buy rating, noting several near-term catalysts that could drive potential upside, although they classified the stock as "Buy/High Risk."

Additionally, Cantor Fitzgerald reiterated its Overweight rating, maintaining a price target of $10.00 after hosting a virtual webinar with Wave’s CEO. The firm emphasized the therapeutic approach targeting activin signaling pathways, which may offer advantages when combined with incretin therapies. These developments reflect growing confidence in Wave Life Sciences’ strategic direction and potential for future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.